Who
Grant Pickering
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Vaxcyte; Director, LeonaBio.
In numbers
- Trades disclosed
- 368
- Buys
- 2
- Sells
- 67
- Bought
- $60K
- Sold
- $43.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 21 Dec 2020
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $1.0M17,056 at $60.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $1.0M17,056 at $60.36 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $211K3,427 at $61.58 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $211K3,427 at $61.58 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $174K2,862 at $60.74 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $174K2,862 at $60.74 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $33K16,198 at $2.03 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $654K11,783 at $55.52 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $247K4,415 at $55.93 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,198 at $0.00 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $42K756 at $55.52 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $14K244 at $55.96 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $35K622 at $55.54 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $21K378 at $55.91 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,198 at $0.00 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $33K16,198 at $2.03 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $654K11,783 at $55.52 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $247K4,415 at $55.93 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $42K756 at $55.52 | filing |
| 27 Jul 2026filed 28 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $14K244 at $55.96 | filing |
News
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPCVX · rttnews.com · 16 Oct 2026Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPCVX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Grant Pickering; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.